Analysis: Syngene International Limited

Growth thesis

Syngene International is a global contract research and manufacturing organization providing drug discovery, development, and biologics manufacturing services. The business is split between research services and CDMO operations, with a strategic expansion into new modalities like antibody drug conjugates, peptides, and oligonucleotides. FY26 revenue guidance was downgraded to a 3-5% decline with EBITDA margins compressed to 22-23%, driven by near-zero Librela volumes persisting through the first half of FY27. While underlying business growth excluding Librela remains high single-digit to low double-digit, the promised revenue ramp from new facilities has not materialized on schedule. Over the next 24 months, the trajectory hinges on the Bayview US biologics facility operationalizing in 2026 and new contract pipelines converting to revenue, with FY27 acting as a flat transition year before stronger growth resumes in FY28. The key execution watchpoint is whether Bayview and Unit 3 can secure meaningful customer contracts to drive capacity utilization and restore margins to the mid-20s.

Why is Syngene International Limited stock rising?

• FY27 expected to be a transition year with broadly flat performance, but H2 meaningfully stronger than H1, with growth weighted towards second half as new contracts ramp up.
• Maintaining EBITDA margins in the mid-20s for FY27 through disciplined cost management and sharper operational execution.
• Librela destocking impact expected to continue in Q1 and Q2 of FY27 with almost no Librela volumes; minor volumes expected towards the end of FY27.
• Expect stronger growth from FY28 onwards as new contract pipeline translates into revenue.
• Investments in AI and digital technologies are aimed at improving speed, productivity, predictability, and scale across discovery, development, and manufacturing, creating differentiated offerings.

Research report

companyname: Syngene International Limited ticker: SYNGENE sector: Contract Research, Development and Manufacturing Organization (CRDMO) - Life Sciences / Pharmaceutical Services Syngene is a Contract Research, Development and Manufacturing Organization (CRDMO) headquartered in Bengaluru, India. It is one of the largest integrated players in the Indian CRDMO space, with a platform that covers drug discovery, development and commercial manufacturing across small molecules, biologics, peptides, a...

Catalysts

capex, new product segment, geographic expansion, management upgrade

Growth guidance

FY26 Revenue decline 3-5%; Operating EBITDA margin 22-23%

Management consistency

mixed